Sana Biotechnology (SANA)
NASDAQ:SANA
US Market

Sana Biotechnology (SANA) Income Statement

235 Followers

Sana Biotechnology Income Statement

Last quarter (Q1 2024), Sana Biotechnology's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, Sana Biotechnology's net income was $-107.47M. See Sana Biotechnology’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 319.81M$ 293.14M$ 272.56M$ 356.91M$ 286.15M$ 141.15M
Operating Income
$ -266.45M$ -293.14M$ -272.56M$ -356.91M$ -286.15M$ -141.15M
Net Non Operating Interest Income Expense
$ 11.00M$ 9.94M$ 3.76M$ 676.00K$ 747.00K$ 2.86M
Other Income Expense
$ -210.00K$ 52.00K$ 674.00K$ -305.00K$ 97.00K$ -29.00K
Pretax Income
$ -368.80M$ -381.22M$ -439.24M$ -355.93M$ -285.31M$ -138.32M
Tax Provision
----$ 0.00$ -7.55M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -473.84M$ -283.25M$ -439.24M$ -355.93M$ -285.31M$ -130.78M
Basic EPS
$ -1.53$ -1.46$ -1.43$ -2.14$ -1.63$ -1.32
Diluted EPS
$ -1.53$ -1.46$ -1.43$ -2.14$ -1.63$ -1.32
Basic Average Shares
$ 804.23M$ 194.54M$ 188.34M$ 166.43M$ 175.31M$ 99.30M
Diluted Average Shares
$ 804.23M$ 194.54M$ 188.34M$ 166.43M$ 175.31M$ 99.30M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
----$ -11.56-
Reported Normalized Diluted E P S
----$ -11.56-
Rent Expense Supplemental
------
Total Expenses
$ 319.81M$ 293.14M$ 272.56M$ 356.91M$ 286.15M$ 141.15M
Net Income From Continuing And Discontinued Operation
$ -308.61M$ -283.25M$ -269.48M$ -355.93M$ -285.31M$ -130.78M
Normalized Income
$ -346.10M$ -341.93M$ -350.36M-$ -285.31M$ -130.78M
Interest Expense
------
EBIT
$ -368.80M$ -381.22M$ -439.24M$ -356.60M$ -286.15M$ -141.15M
EBITDA
$ -175.08M$ -343.39M$ -411.53M$ -338.66M$ -280.23M$ -139.33M
Currency in USD

Sana Biotechnology Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis